[go: up one dir, main page]

NL300803I2 - - Google Patents

Download PDF

Info

Publication number
NL300803I2
NL300803I2 NL300803C NL300803C NL300803I2 NL 300803 I2 NL300803 I2 NL 300803I2 NL 300803 C NL300803 C NL 300803C NL 300803 C NL300803 C NL 300803C NL 300803 I2 NL300803 I2 NL 300803I2
Authority
NL
Netherlands
Application number
NL300803C
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22821718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300803(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of NL300803I2 publication Critical patent/NL300803I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
NL300803C 2000-07-21 2016-04-22 NL300803I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22002100P 2000-07-21 2000-07-21
PCT/US2001/023104 WO2002008241A2 (en) 2000-07-21 2001-07-20 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same

Publications (1)

Publication Number Publication Date
NL300803I2 true NL300803I2 (nl) 2016-06-30

Family

ID=22821718

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300803C NL300803I2 (nl) 2000-07-21 2016-04-22

Country Status (37)

Country Link
US (10) US20020119443A1 (nl)
EP (3) EP3235823A1 (nl)
JP (4) JP4651264B2 (nl)
KR (2) KR100749160B1 (nl)
CN (2) CN100402539C (nl)
AP (1) AP1466A (nl)
AU (3) AU8294101A (nl)
BE (1) BE2016C018I2 (nl)
BG (1) BG66037B1 (nl)
BR (1) BRPI0112646B8 (nl)
CA (3) CA2416757C (nl)
CY (2) CY2016008I1 (nl)
CZ (2) CZ304734B6 (nl)
DK (2) DK2682397T3 (nl)
EA (1) EA004926B1 (nl)
EE (1) EE05366B1 (nl)
ES (2) ES2536972T5 (nl)
FR (1) FR16C0013I2 (nl)
HK (1) HK1243711A1 (nl)
HR (2) HRP20160074B1 (nl)
HU (2) HU230960B1 (nl)
IL (1) IL153658A0 (nl)
IS (1) IS2985B (nl)
LT (2) LT2682397T (nl)
LU (1) LU93029I2 (nl)
MX (1) MXPA03000587A (nl)
NL (1) NL300803I2 (nl)
NO (6) NO336718B1 (nl)
NZ (3) NZ535408A (nl)
OA (1) OA12393A (nl)
PL (1) PL213214B1 (nl)
PT (2) PT1301519E (nl)
SI (2) SI2682397T1 (nl)
TR (1) TR200300055T2 (nl)
UA (1) UA75889C2 (nl)
WO (1) WO2002008241A2 (nl)
ZA (1) ZA200210271B (nl)

Families Citing this family (240)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20160074B1 (hr) 2000-07-21 2021-09-03 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
US7388002B2 (en) * 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
PL374525A1 (en) * 2001-11-14 2005-10-31 Biocryst Pharmaceuticals, Inc. Nucleosides preparation thereof and use as inhibitors of rna viral polymerases
IL164491A0 (en) * 2002-04-26 2005-12-18 Gilead Sciences Inc Non nucleoside reverse transcriptase inhibitors
US20050239054A1 (en) * 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
US7214668B2 (en) 2002-05-13 2007-05-08 Metabasis Therapeutics, Inc. Phosphonic acid based prodrugs of PMEA and its analogues
US20060234982A1 (en) * 2003-01-14 2006-10-19 Dahl Terrence C Compositions and methods for combination antiviral therapy
MXPA05011297A (es) * 2003-04-25 2006-05-25 Gilead Sciences Inc Analogos antivirales de fosfonato.
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7300924B2 (en) * 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
CA2522845A1 (en) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
CN101410120A (zh) * 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
US7432261B2 (en) * 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
WO2004096287A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
EP1678321A1 (en) * 2003-10-24 2006-07-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
WO2005044308A1 (en) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
BRPI0418031A (pt) * 2003-12-22 2007-04-17 Gilead Sciences Inc inibidores de quinase fosfonato-substituìdos
CA2548753A1 (en) * 2003-12-22 2005-07-14 Gilead Sciences, Inc. 4-substituted carbovir and abacavir-derivatives as well as related compounds with hiv and hcv antiviral activity
US20050153990A1 (en) * 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
RS52433B (sr) * 2003-12-30 2013-02-28 Gilead Sciences Inc. Nukleozid-fosfonati i njihovi analozi za lečenje hpv infekcija
NZ548532A (en) * 2004-01-21 2009-09-25 Gilead Sciences Inc Use of adefovir or tenofovir for inhibiting MMTV-like viruses involved in breast cancer and primary biliary cirrhosis
US8416242B1 (en) 2004-05-14 2013-04-09 Nvidia Corporation Method and system for interpolating level-of-detail in graphics processors
US8432394B1 (en) 2004-05-14 2013-04-30 Nvidia Corporation Method and system for implementing clamped z value interpolation in a raster stage of a graphics pipeline
US8411105B1 (en) 2004-05-14 2013-04-02 Nvidia Corporation Method and system for computing pixel parameters
US7079156B1 (en) 2004-05-14 2006-07-18 Nvidia Corporation Method and system for implementing multiple high precision and low precision interpolators for a graphics pipeline
KR20070029196A (ko) 2004-06-08 2007-03-13 메타베이시스 테라퓨틱스, 인크. 고리 에스테르의 루이스 산 매개 합성
SI1778251T1 (sl) * 2004-07-27 2011-07-29 Gilead Sciences Inc Nukleozidni fosfonatni konjugati kot sredstva proti HIV
EP1868628B1 (en) 2005-04-08 2014-06-11 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
WO2006110656A2 (en) * 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of viral infections and other medical disorders
CN100359315C (zh) * 2005-05-26 2008-01-02 林维宣 兽药残留能力验证样品及制备方法
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
CN100396689C (zh) * 2006-03-07 2008-06-25 中国医学科学院医药生物技术研究所 一组具有抑制hiv-1/hbv病毒复制活性的替诺福韦单酯化合物
EP2020996B1 (en) 2006-05-16 2011-11-23 Gilead Sciences, Inc. Method and compositions for treating hematological malignancies
ES2532502T3 (es) * 2006-07-12 2015-03-27 Mylan Laboratories Limited Proceso para la preparación de tenofovir
US7951789B2 (en) * 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8105489B2 (en) * 2007-06-26 2012-01-31 The University Of Wyoming Research Corporation Treatment and prevention systems for acid mine drainage and halogenated contaminants
US8441497B1 (en) * 2007-08-07 2013-05-14 Nvidia Corporation Interpolation of vertex attributes in a graphics processor
EP3085377A1 (en) * 2008-01-25 2016-10-26 Chimerix, Inc. Methods of treating viral infections
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
NZ588796A (en) 2008-04-25 2012-07-27 Cipla Ltd Crystalline form of tenofovir disoproxil and a process for its preparation
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
AU2009277172B2 (en) * 2008-07-02 2014-05-29 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
PE20110219A1 (es) 2008-07-08 2011-03-31 Gilead Sciences Inc Sales del compuesto n-[(s)({[(2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il]oxi}metil)fenoxifosfinoil]-l-alaninato de etilo como inhibidores de vih
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
CA2748034A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Purified 2'-deoxy'2'-fluoro-2'-c-methyl-nucleoside-phosphoramidate prodrugs for the treatment of viral infections
MX2011006891A (es) 2008-12-23 2011-10-06 Pharmasset Inc Fosforamidatos de nucleosidos.
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
WO2011011519A1 (en) 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
CA2773773C (en) 2009-09-21 2019-04-23 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
PL2534150T3 (pl) 2010-02-12 2017-09-29 Chimerix, Inc. Sposoby leczenia infekcji wirusowej
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
SG184323A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasett Llc Stereoselective synthesis of phosphorus containing actives
CN102917585A (zh) 2010-04-01 2013-02-06 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
CA2797601A1 (en) 2010-04-26 2011-11-10 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
KR101995598B1 (ko) 2010-07-19 2019-07-02 길리애드 사이언시즈, 인코포레이티드 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법
SG186830A1 (en) 2010-07-22 2013-02-28 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
EP3042910B1 (en) 2010-11-30 2019-01-09 Gilead Pharmasset LLC 2'-spiro-nucleosides for use in the therapy of hepatitis c
RU2606845C2 (ru) 2010-12-10 2017-01-10 СИГМАФАРМ ЛЭБОРЭТОРИЗ, ЭлЭлСи Высокостабильные композиции перорально активных аналогов нуклеотидов или перорально активных пролекарств аналогов нуклеотидов
ZA201103820B (en) 2010-12-13 2012-01-25 Laurus Labs Private Ltd Process for the preparation of tenofovir
JP2014514295A (ja) 2011-03-31 2014-06-19 アイディニックス ファーマシューティカルズ インコーポレイテッド ウイルス感染の治療のための化合物および薬学的組成物
WO2012154698A2 (en) * 2011-05-06 2012-11-15 Mckenna Charles E Method to improve antiviral activity of nucleotide analogue drugs
WO2012159047A1 (en) 2011-05-19 2012-11-22 Gilead Sciences, Inc. Processes and intermediates for preparing anti-hiv agents
AU2014271320B2 (en) * 2011-08-16 2017-02-23 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
CN110343135A (zh) * 2011-08-16 2019-10-18 吉利德科学公司 替诺福韦艾拉酚胺(tenofovir alafenamide)半反丁烯二酸盐
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
ES2734495T3 (es) 2011-12-22 2019-12-10 Geron Corp Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros
NZ629896A (en) 2012-02-03 2016-03-31 Gilead Sciences Inc Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
AU2012327170A1 (en) 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
CN103665043B (zh) * 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
GB201215696D0 (en) * 2012-09-03 2012-10-17 Ithemba Pharmaceuticals Pty Ltd A process for the preparation of (R)-9-[2-(Phosphonometh-Oxy)propyl]adenine (PMPA)
SI3333173T1 (sl) * 2012-10-03 2019-08-30 Gilead Sciences, Inc. Postopki za pripravo analogov protivirusnega nukleotida
US9227990B2 (en) 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
CN102899327B (zh) * 2012-11-06 2014-06-11 清华大学深圳研究生院 一种抗病毒的小核酸及其温度敏感型凝胶制剂与应用
US9730940B2 (en) * 2012-11-16 2017-08-15 Merck Sharp & Dohme Purine inhibitors of human phosphatidylinositol 3-kinase delta
CN103848869B (zh) * 2012-12-04 2016-12-21 上海医药工业研究院 制备替诺福韦的方法
CN103848868B (zh) * 2012-12-04 2017-04-12 蚌埠丰原涂山制药有限公司 制备替诺福韦的方法
LT2950786T (lt) 2013-01-31 2020-03-10 Gilead Pharmasset Llc Dviejų antivirusinių junginių preparatų kompozicija
CN104072539B (zh) * 2013-03-25 2017-03-29 安徽贝克联合制药有限公司 替诺福韦双(4‑乙酰氨基苯酚氧基)酯及其制备方法和其应用
WO2014187314A1 (zh) * 2013-05-21 2014-11-27 成都先导药物开发有限公司 一种药物靶标捕获方法
EP3004121A1 (en) 2013-06-07 2016-04-13 Cipla Limited An efficient process for separation of diastereomers of 9-[(r)-2-[[(r,s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
WO2015040640A2 (en) * 2013-09-20 2015-03-26 Laurus Labs Private Limited An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof
EP2860185A1 (en) 2013-10-09 2015-04-15 Zentiva, k.s. An improved process for the preparation of Tenofovir disoproxil and pharmaceutically acceptable salts thereof
WO2015079455A2 (en) * 2013-11-27 2015-06-04 Laurus Labs Private Limited A recycling process for preparing tenofovir alafenamide diastereomers
EP3077404B1 (en) * 2014-01-14 2020-10-07 Mylan Laboratories Ltd. Purification of tenofovir alafenamide and its intermediates
TWI660965B (zh) * 2014-01-15 2019-06-01 美商基利科學股份有限公司 泰諾福韋之固體形式
CN104804042B (zh) * 2014-01-24 2018-01-19 齐鲁制药有限公司 核苷酸膦酸酯类化合物、其药物组合物、制备方法及用途
WO2015120057A1 (en) 2014-02-05 2015-08-13 Gilead Sciences, Inc. Pharmaceutical combinations against co-infection with hiv and tuberculosis
EP3105238A4 (en) 2014-02-13 2017-11-08 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2015127848A1 (zh) * 2014-02-27 2015-09-03 四川海思科制药有限公司 一种取代的氨基磷酸酯类衍生物、其制备方法及其应用
CN105001262B (zh) * 2014-04-18 2017-09-01 四川海思科制药有限公司 芳基取代的磷酰胺类衍生物及其在医学上的应用
WO2015161785A1 (zh) * 2014-04-21 2015-10-29 四川海思科制药有限公司 氨基磷酸酯类衍生物制备方法及其中间体和中间体的制备方法
CN105085571A (zh) * 2014-05-20 2015-11-25 四川海思科制药有限公司 替诺福韦艾拉酚胺复合物及其制备方法和用途
WO2015197006A1 (zh) * 2014-06-25 2015-12-30 四川海思科制药有限公司 一种取代的氨基酸硫酯类化合物、其组合物及应用
EP3164136A4 (en) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
DK3194411T3 (da) 2014-09-15 2022-05-30 Univ California Nukleotidanaloger
CN106687467A (zh) * 2014-09-30 2017-05-17 韩美精密化学株式会社 高纯度（r）‑9‑[2‑（磷酰甲氧基）丙基]腺嘌呤的制备方法
KR101703257B1 (ko) 2014-09-30 2017-02-06 한미정밀화학주식회사 고순도의 (r)-9-[2-(포스포노메톡시)프로필]아데닌의 제조방법
KR101703258B1 (ko) 2014-12-30 2017-02-06 한미정밀화학주식회사 고순도의 (r)-9-[2-(포스포노메톡시)프로필]아데닌의 제조방법
EP3203995A4 (en) 2014-10-09 2019-05-15 Board of Regents of the University of Nebraska COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS
TWI687432B (zh) 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
CN108148094A (zh) * 2014-11-12 2018-06-12 四川海思科制药有限公司 一种替诺福韦艾拉酚胺富马酸盐晶型c及其制备方法和用途
CN104558036A (zh) * 2014-12-11 2015-04-29 杭州和泽医药科技有限公司 一种替诺福韦艾拉酚胺半反丁烯二酸盐晶型及其制备方法
US20170348334A1 (en) 2015-01-03 2017-12-07 Mylan Laboratories Limited Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof
US20180148774A1 (en) * 2015-05-16 2018-05-31 Godx, Inc Point of need testing device and methods of use thereof
CN106188139B (zh) 2015-05-29 2020-02-18 江苏天士力帝益药业有限公司 替诺福韦单苄酯磷酸酰胺前药、其制备方法及应用
CZ2015384A3 (cs) 2015-06-05 2016-12-14 Zentiva, K.S. Pevné formy Tenofovir alafenamidu
EP4606784A3 (en) * 2015-06-17 2025-11-05 Gilead Sciences, Inc. Co-crystals, salts and solid forms of tenofovir alafenamide
CN119606990A (zh) 2015-06-30 2025-03-14 吉利德科学公司 包含替诺福韦和恩曲他滨的药物制剂
TWI639598B (zh) 2015-08-10 2018-11-01 美商默沙東藥廠 抗病毒β－胺基酸酯磷酸二醯胺化合物
TWI616452B (zh) * 2015-08-26 2018-03-01 Preparation method of nucleoside analog and intermediate thereof
TWI620754B (zh) * 2015-08-26 2018-04-11 Method for preparing amino phosphate derivative and preparation method thereof
TWI616453B (zh) * 2015-08-27 2018-03-01 Substituted amino acid thioester compounds, compositions and uses thereof
WO2017037608A1 (en) * 2015-08-28 2017-03-09 Laurus Labs Private Limited Solid forms of tenofovir alafenamide and salts thereof, processes for its preparation and pharmaceutical compositions thereof
MX394858B (es) 2015-09-16 2025-03-24 Gilead Sciences Inc Compuestos de formula i para usarse en el tratamiento de infecciones por virus arenaviridae y coronaviridae
PE20181207A1 (es) 2015-11-09 2018-07-23 Gilead Sciences Inc Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana
CN106800573B (zh) * 2015-11-25 2020-03-10 四川海思科制药有限公司 一种核苷酸膦酸酯一水合物及其制备方法和在医药上的应用
US10745428B2 (en) 2015-12-10 2020-08-18 Idenix Pharmaceuticals Llc Antiviral phosphodiamide prodrugs of tenofovir
CN106866737B (zh) * 2015-12-11 2020-11-20 南京圣和药物研发有限公司 膦酸衍生物及其应用
EP3390413B1 (en) 2015-12-15 2020-08-19 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
WO2017118928A1 (en) 2016-01-06 2017-07-13 Lupin Limited Process for the separation of diastereomers of tenofovir alafenamide
WO2017134089A1 (en) 2016-02-02 2017-08-10 Sandoz Ag Crystalline forms of tenofovir alafenamide monofumarate
CN107709288A (zh) * 2016-02-03 2018-02-16 四川海思科制药有限公司 一种磷酰胺衍生物及制备方法和用途
CN108350007B (zh) * 2016-03-01 2020-04-10 深圳市塔吉瑞生物医药有限公司 一种取代的腺嘌呤化合物及其药物组合物
CN107179355B (zh) * 2016-03-11 2021-08-10 广东东阳光药业有限公司 一种分离检测替诺福韦艾拉酚胺及其有关物质的方法
CZ2016156A3 (cs) 2016-03-17 2017-09-27 Zentiva, K.S. Způsob přípravy diastereomerně čistého Tenofoviru Alafenamidu nebo jeho solí
CN107226826A (zh) * 2016-03-25 2017-10-03 江苏奥赛康药业股份有限公司 替诺福韦艾拉酚胺富马酸盐化合物及其药物组合物
WO2017211325A1 (zh) * 2016-06-05 2017-12-14 上海诚妙医药科技有限公司 富马酸替诺福韦艾拉酚胺盐的新晶型、制备方法及其用途
CN106543227B (zh) * 2016-06-20 2018-02-02 杭州和泽医药科技有限公司 一种腺嘌呤衍生物的膦酸酯前药及其在医药上的应用
WO2017221189A1 (en) * 2016-06-22 2017-12-28 Laurus Labs Limited An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof
CN106317116A (zh) * 2016-08-19 2017-01-11 张红利 磷酰胺核苷类化合物及其药学上可接受的盐与应用、药物组合物
CA3021227C (en) 2016-08-19 2020-11-03 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
EP3503895B1 (en) 2016-08-25 2021-09-15 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
CN106380484A (zh) * 2016-08-29 2017-02-08 杭州百诚医药科技股份有限公司 一种替诺福韦艾拉酚胺的新晶型及其制备方法
WO2018042331A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018051250A1 (en) 2016-09-14 2018-03-22 Viiv Healthcare Company Combination comprising tenofovir alafenamide, bictegravir and 3tc
US10736908B2 (en) 2016-10-26 2020-08-11 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
CN106565785B (zh) * 2016-11-09 2019-11-12 周雨恬 一种具有抗hbv/hiv活性的核苷氨基磷酸酯类化合物及其盐和用途
CN108129514A (zh) * 2016-12-01 2018-06-08 北京美倍他药物研究有限公司 磷酸/膦酸衍生物的单一异构体及其医药用途
RU2019122625A (ru) * 2016-12-22 2021-01-22 Мерк Шарп И Доум Корп. Противовирусные бензиламин-фосфодиамидные соединения
BR112019013017A2 (pt) 2016-12-22 2020-01-14 Idenix Pharmaceuticals Llc compostos de éster alifático antiviral de tenofovir ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e uso dos mesmos
WO2018115046A1 (en) 2016-12-23 2018-06-28 Sandoz Ag Crystalline solid forms of tenofovir alafenamide
TWI714820B (zh) 2017-01-31 2021-01-01 美商基利科學股份有限公司 替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型
WO2018153977A1 (en) 2017-02-24 2018-08-30 Hexal Ag Stable composition of tenofovir alafenamide
RU2659388C1 (ru) 2017-02-28 2018-07-02 Васильевич Иващенко Александр Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
RU2647576C1 (ru) * 2017-02-28 2018-03-16 Васильевич Иващенко Александр Циклобутил (S)-2-[[[(R)-2-(6-аминопурин-9-ил)-1-метил-этокси]метил-фенокси-фосфорил]амино]-пропаноаты, способ их получения и применения
CN106866739B (zh) * 2017-03-10 2018-11-02 华东师范大学 一种(r)-1-(6-氨基-9h-嘌呤-9-基)2-苯酯的制备方法
EP3595672B1 (en) 2017-03-14 2023-09-06 Gilead Sciences, Inc. Compounds for use in methods of treating feline coronavirus infections
EP3600332B1 (en) 2017-03-20 2023-12-13 The United States of America, as represented by the Secretary, Department of Health and Human Services Hiv post-exposure prophylaxis
CN108794530A (zh) * 2017-04-26 2018-11-13 上海医药工业研究院 一种替诺福韦丙酚酰胺盐晶型及其制备方法和用途
EP4219513A1 (en) 2017-05-01 2023-08-02 Gilead Sciences, Inc. Crystalline form of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
KR102379965B1 (ko) * 2017-05-19 2022-03-29 주식회사 종근당 테노포비르의 효율적인 제조방법
CN107266499B (zh) * 2017-06-05 2019-07-02 珠海优润医药科技有限公司 一种抗病毒化合物及其制备方法
WO2019003251A1 (en) 2017-06-30 2019-01-03 Cipla Limited PHARMACEUTICAL COMPOSITIONS
TW201919648A (zh) 2017-07-11 2019-06-01 美商基利科學股份有限公司 用於治療病毒感染之含rna聚合酶抑制劑與環糊精的組合物
WO2019021319A1 (en) 2017-07-27 2019-01-31 Cipla Limited PHARMACEUTICAL COMPOSITIONS
PL3661937T3 (pl) 2017-08-01 2021-12-20 Gilead Sciences, Inc. Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
CN107655987B (zh) * 2017-09-08 2020-11-03 厦门蔚扬药业有限公司 一种替诺福韦艾拉酚胺及其异构体的hplc检测方法
CN107522743A (zh) * 2017-09-30 2017-12-29 深圳科兴生物工程有限公司 一种半富马酸替诺福韦艾拉酚胺工业化连续生产方法
US20190151307A1 (en) 2017-10-24 2019-05-23 Gilead Sciences, Inc. Methods of treating patients co-infected with a virus and tuberculosis
CN109942633B (zh) * 2017-12-20 2021-08-31 上海新礼泰药业有限公司 替诺福韦艾拉酚胺中间体的制备方法
CN109942632B (zh) * 2017-12-20 2021-08-31 上海博志研新药物研究有限公司 替诺福韦艾拉酚胺中间体的制备方法
WO2019130354A1 (en) 2017-12-30 2019-07-04 Cipla Limited Polymorphic forms of (9-[(r)-2-[[(s)-[[(s)-1- (isopropoxycarbonyl)ethyl]amino]phenoxy phosphinyl]methoxy]propyl] adenine and pharmaceutically acceptable salts thereof
JP2021509907A (ja) 2018-01-09 2021-04-08 リガンド・ファーマシューティカルズ・インコーポレイテッド アセタール化合物およびその治療的使用
EP4335496A3 (en) * 2018-01-10 2025-08-27 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
EP3737359A4 (en) * 2018-01-12 2021-11-03 Board of Regents of the University of Nebraska ANTIVIRAL MEDICINES AND FORMULATIONS OF THEM
EP3752495B1 (en) 2018-02-15 2023-07-19 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
CA3090280C (en) 2018-02-16 2025-11-25 Gilead Sciences, Inc. METHODS AND INTERMEDIARIES FOR PREPARING THERAPEUTIC COMPOUNDS USEFUL IN THE TREATMENT OF A RETROVIRIDAE VIRAL INFECTION
CN108101943B (zh) * 2018-02-28 2020-11-24 顾世海 一种替诺福韦前药或可药用盐及其在医药上的应用
WO2019199756A1 (en) 2018-04-09 2019-10-17 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
CN120078775A (zh) 2018-07-16 2025-06-03 吉利德科学公司 用于治疗hiv的衣壳抑制剂
WO2020018399A1 (en) 2018-07-19 2020-01-23 Merck Sharp & Dohme Corp. Phosphinic amide prodrugs of tenofovir
KR102879944B1 (ko) 2018-09-19 2025-11-03 길리애드 사이언시즈, 인코포레이티드 Hiv 예방용 인테그라제 억제제
EP4122537A1 (en) 2019-03-22 2023-01-25 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
WO2021011692A1 (en) 2019-07-17 2021-01-21 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
CA3146263A1 (en) 2019-07-19 2021-01-28 Jose Gerardo Garcia Lerma Hiv pre-exposure prophylaxis
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
WO2021035214A1 (en) * 2019-08-22 2021-02-25 Emory University Nucleoside prodrugs and uses related thereto
CN114761014A (zh) * 2019-09-20 2022-07-15 雅培快速诊断国际无限公司 针对替诺福韦及其衍生物的抗体
AU2020391466B2 (en) 2019-11-26 2024-05-23 Gilead Sciences, Inc. Capsid inhibitors for the prevention of HIV
EP4096678A1 (en) 2020-01-27 2022-12-07 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
WO2021165995A1 (en) 2020-02-20 2021-08-26 Cipla Limited Novel salts and/or co-crystals of tenofovir alafenamide
CN115298181B (zh) 2020-03-12 2024-08-16 吉利德科学公司 制备1’-氰基核苷的方法
CA3169348A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
WO2021202669A2 (en) 2020-04-01 2021-10-07 Reyoung Corporation Nucleoside and nucleotide conjugate compounds and uses thereof
EP4132651A1 (en) 2020-04-06 2023-02-15 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
KR20210125298A (ko) 2020-04-08 2021-10-18 주식회사 파마코스텍 테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법
WO2021216427A1 (en) 2020-04-21 2021-10-28 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds
US12552820B2 (en) 2020-04-21 2026-02-17 Ligand Pharmaceuticals Incorporated Benzyloxy phosph(on)ate compounds
ES3041698T3 (en) 2020-05-29 2025-11-13 Gilead Sciences Inc Remdesivir for the treatment of viral infections
US11939347B2 (en) 2020-06-24 2024-03-26 Gilead Sciences, Inc. 1′-cyano nucleoside analogs and uses thereof
CN115996925A (zh) 2020-06-25 2023-04-21 吉利德科学公司 用于治疗hiv的衣壳抑制剂
CN113970612B (zh) * 2020-07-22 2023-08-01 北京四环制药有限公司 一种高效液相色谱法测定丙酚替诺福韦有关物质的方法
CA3190702A1 (en) 2020-08-27 2022-03-03 Elaine Bunyan Compounds and methods for treatment of viral infections
CN112336695B (zh) * 2020-09-28 2023-01-03 华北制药华坤河北生物技术有限公司 一种富马酸丙酚替诺福韦片剂及其制备方法和有关物质的检测方法
CA3195799A1 (en) 2020-11-11 2022-05-19 Stephen R. Martin Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies
US11667656B2 (en) 2021-01-27 2023-06-06 Apotex Inc. Crystalline forms of Tenofovir alafenamide
CN113075307B (zh) * 2021-03-08 2025-03-11 瑞阳制药股份有限公司 富马酸丙酚替诺福韦异构体的检测方法
CN113214322B (zh) * 2021-04-30 2022-10-25 山东立新制药有限公司 替诺福韦绿色环保的制备方法
WO2022251594A1 (en) * 2021-05-27 2022-12-01 Antios Therapeutics, Inc. Pharmacokinetics and dose-related improvments in subjects treated with phosphoramidate clevudine prodrugs
WO2023102239A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
CN118355020A (zh) 2021-12-03 2024-07-16 吉利德科学公司 Hiv病毒感染的治疗性化合物
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
CN114369120A (zh) * 2022-01-28 2022-04-19 石家庄龙泽制药股份有限公司 一种丙酚替诺福韦关键中间体的制备方法
CR20240363A (es) 2022-03-02 2024-10-25 Gilead Sciences Inc Compuestos y métodos para el tratamiento de infecciones virales.
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024006982A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
AU2023310177A1 (en) 2022-07-21 2025-03-06 Antiva Biosciences, Inc. Compositions and dosage forms for treatment of hpv infection and hpv-induced neoplasia
KR20250051732A (ko) 2022-08-26 2025-04-17 길리애드 사이언시즈, 인코포레이티드 광범위 중화 항체를 위한 투여 및 일정 요법
US20240226130A1 (en) 2022-10-04 2024-07-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
AU2024240009A1 (en) 2023-03-17 2025-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treatment of age-related macular degeneration
TW202444363A (zh) 2023-04-19 2024-11-16 美商基利科學股份有限公司 殼體抑制劑之給藥方案
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
TW202504592A (zh) 2023-05-31 2025-02-01 美商基利科學股份有限公司 固體形式
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
TW202515549A (zh) 2023-10-11 2025-04-16 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2025080863A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202530226A (zh) 2023-10-11 2025-08-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20250230163A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250333424A1 (en) 2024-03-01 2025-10-30 Gilead Sciences, Inc. Antiviral compounds
US20250296932A1 (en) 2024-03-01 2025-09-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
WO2025184452A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
EP4640214A1 (en) 2024-03-28 2025-10-29 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A tablet comprising tenofovir alafenamide monofumarate
US20260007683A1 (en) 2024-06-14 2026-01-08 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
CN118652277A (zh) * 2024-08-19 2024-09-17 成都工业学院 一种用于治疗癌症疾病的化合物的制备方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS233665B1 (en) 1983-01-06 1985-03-14 Antonin Holy Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene
CS263952B1 (en) 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
CS263951B1 (en) 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5650510A (en) 1986-11-18 1997-07-22 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
US5057301A (en) 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
US5053215A (en) * 1988-05-26 1991-10-01 University Of Florida NMR-assayable ligand-labelled trifluorothymidine containing composition and method for diagnosis of HSV infection
US5744600A (en) 1988-11-14 1998-04-28 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Phosphonomethoxy carbocyclic nucleosides and nucleotides
US5688778A (en) 1989-05-15 1997-11-18 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
JP2648516B2 (ja) 1989-07-27 1997-09-03 ダイセル化学工業株式会社 立体異性体の分離法
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
JP2925753B2 (ja) 1990-02-23 1999-07-28 ダイセル化学工業株式会社 光学異性体の分離方法
US5302585A (en) 1990-04-20 1994-04-12 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
PT97407B (pt) * 1990-04-20 1998-08-31 Rega Stichting Processo para a preparacao de (r)-9-{2-(fosfono-metoxi)-propil}-guanina
SK280313B6 (sk) 1990-04-24 1999-11-08 �Stav Organick� Chemie A Biochemie Av �R N-(3-fluór-2-fosfonylmetoxypropyl)deriváty purínov
US5627165A (en) * 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
CS276072B6 (en) 1990-08-06 1992-03-18 Ustav Organicke Chemie A Bioch (2R)-2-/DI(2-PROPYL)PHOSPHONYLMETHOXY/-3-p-TOLUENESULFONYLOXY -1- TRIMETHYLACETOXYPROPANE AND PROCESS FOR PREPARING THEREOF
KR100221981B1 (ko) 1990-08-10 1999-09-15 안토닌 포레이트 뉴클레오티드의 신규 제조방법
ATE167679T1 (de) * 1990-09-14 1998-07-15 Acad Of Science Czech Republic Wirkstoffvorläufer von phosphonaten
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5208221A (en) 1990-11-29 1993-05-04 Bristol-Myers Squibb Company Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives
CZ284678B6 (cs) 1991-05-20 1999-01-13 Ústav Organické Chemie A Biochemie Avčr Di(2-propyl)estery 1-fluor-2-fosfonomethoxy-3-p -toluensulfonyloxypropanů, způsob jejich přípravy a použití
JP3010816B2 (ja) 1991-08-22 2000-02-21 ダイセル化学工業株式会社 光学分割における光学異性体と溶媒との回収方法、溶媒の循環使用方法、および光学異性体の再利用方法
US5498752A (en) 1991-08-22 1996-03-12 Daicel Chemical Industries, Ltd. Process for recovering optical isomers and solvent, process for using solvent by circulation and process for reusing optical isomers in optical resolution
ATE151432T1 (de) 1991-10-11 1997-04-15 Acad Of Science Czech Republic Antivirale acyclische phosphonomethoxyalkyl substituierte, alkenyl und alkynyl purin und pyrimidin-derivate
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
IL106998A0 (en) * 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
US6413949B1 (en) * 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
US5656745A (en) * 1993-09-17 1997-08-12 Gilead Sciences, Inc. Nucleotide analogs
EP0719273B1 (en) 1993-09-17 2010-11-03 Gilead Sciences, Inc. Nucleotide analogs
AU690587B2 (en) * 1993-09-17 1998-04-30 Gilead Sciences, Inc. Method for dosing therapeutic compounds
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
ATE245161T1 (de) * 1995-05-26 2003-08-15 Genta Inc Verfahren zur synthese von phosphororganischen verbindungen
US5717095A (en) * 1995-12-29 1998-02-10 Gilead Sciences, Inc. Nucleotide analogs
WO1997024361A1 (en) 1995-12-29 1997-07-10 Gilead Sciences, Inc. Nucleotide analogs
US5874577A (en) * 1996-04-03 1999-02-23 Medichem Research, Inc. Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
JP4033494B2 (ja) * 1996-07-26 2008-01-16 ギリヤド サイエンシーズ， インコーポレイテッド ヌクレオチドアナログ
US5739314A (en) 1997-04-25 1998-04-14 Hybridon, Inc. Method for synthesizing 2'-O-substituted pyrimidine nucleosides
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
PT1243590E (pt) 1997-07-25 2005-05-31 Gilead Sciences Inc Composicao de analogos nuclotidicos e metodo de sintese
ATE277936T1 (de) 1997-07-25 2004-10-15 Gilead Sciences Inc Verfahren zur herstellung von adefovir dipivoxil
JP4465109B2 (ja) * 1997-12-17 2010-05-19 エンゾン ファーマシューティカルズ，インコーポレーテッド アミノ及びヒドロキシル含有生物活性剤のポリマープロドラッグ
US6245750B1 (en) * 1998-01-23 2001-06-12 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
US6169078B1 (en) * 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances
US6348185B1 (en) * 1998-06-20 2002-02-19 Washington University School Of Medicine Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US6169879B1 (en) * 1998-09-16 2001-01-02 Webtv Networks, Inc. System and method of interconnecting and using components of home entertainment system
GB9821058D0 (en) † 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
TWI230618B (en) 1998-12-15 2005-04-11 Gilead Sciences Inc Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
KR20010102082A (ko) † 1999-02-12 2001-11-15 그레이엄 브레레톤, 레슬리 에드워즈 항바이러스제로서의 포스포르아미데이트, 및 (1ｒ, 시스)-4-(6-아미노-9ｈ-푸린-9-일)-2-시클로펜텐-1-메탄올의 모노-, 디-, 및 트리-포스페이트 에스테르
HRP20160074B1 (hr) * 2000-07-21 2021-09-03 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
AU2002220979A1 (en) * 2000-10-13 2002-04-22 Xigen Sa Intracellular delivery of biological effectors by novel transporter peptide sequences
US20020119433A1 (en) * 2000-12-15 2002-08-29 Callender Thomas J. Process and system for creating and administering interview or test

Also Published As

Publication number Publication date
HUP0301307A2 (hu) 2003-09-29
WO2002008241A2 (en) 2002-01-31
JP5111551B2 (ja) 2013-01-09
CA2725819A1 (en) 2002-01-31
IS6689A (is) 2003-01-17
NO20030270D0 (no) 2003-01-20
AU2005225039A1 (en) 2005-11-10
CA2416757A1 (en) 2002-01-31
HUS1900027I1 (hu) 2021-03-29
HRP20160074B1 (hr) 2021-09-03
CN1706855A (zh) 2005-12-14
LT2682397T (lt) 2017-06-12
HUP0301307A3 (en) 2005-12-28
NO2023006I1 (no) 2023-02-03
DK2682397T3 (da) 2017-06-19
JP4651264B2 (ja) 2011-03-16
BRPI0112646B8 (pt) 2021-05-25
HRP20160074A2 (hr) 2016-03-11
ES2536972T3 (es) 2015-06-01
US20050124583A1 (en) 2005-06-09
US7803788B2 (en) 2010-09-28
IL153658A0 (en) 2003-07-06
MXPA03000587A (es) 2004-04-05
NO20131717L (no) 2003-03-20
KR20060105807A (ko) 2006-10-11
US20060024659A1 (en) 2006-02-02
CN1291994C (zh) 2006-12-27
HRP20160074A8 (hr) 2016-07-29
CA2893174A1 (en) 2002-01-31
NO2016006I1 (no) 2016-04-19
EE05366B1 (et) 2010-12-15
JP5063554B2 (ja) 2012-10-31
EA200300188A1 (ru) 2003-06-26
LU93029I2 (fr) 2016-06-14
EP1301519B1 (en) 2015-02-25
EP2682397A1 (en) 2014-01-08
KR100767432B1 (ko) 2007-10-17
EP1301519B2 (en) 2021-11-10
EA004926B1 (ru) 2004-10-28
US20020119443A1 (en) 2002-08-29
HK1054238A1 (en) 2003-11-21
NZ535408A (en) 2006-09-29
FR16C0013I2 (fr) 2016-09-09
BG107572A (bg) 2003-11-28
AU2001282941B2 (en) 2006-04-27
US7390791B2 (en) 2008-06-24
CN100402539C (zh) 2008-07-16
HU230960B1 (hu) 2019-06-28
CN1443189A (zh) 2003-09-17
KR100749160B1 (ko) 2007-08-14
KR20030022295A (ko) 2003-03-15
SI1301519T1 (sl) 2015-07-31
EE200300029A (et) 2004-10-15
CZ304886B6 (cs) 2015-01-07
TR200300055T2 (tr) 2004-12-21
ZA200210271B (en) 2003-12-31
HRP20030047B1 (hr) 2016-02-26
AU8294101A (en) 2002-02-05
UA75889C2 (uk) 2006-06-15
NZ536942A (en) 2006-03-31
HUS000494I2 (hu) 2021-03-29
BE2016C018I2 (nl) 2020-08-20
AU2005225039B2 (en) 2008-09-25
EP1301519A2 (en) 2003-04-16
JP2009062383A (ja) 2009-03-26
BG66037B1 (bg) 2010-11-30
AP1466A (en) 2005-09-22
DK1301519T3 (en) 2015-05-26
JP2010174033A (ja) 2010-08-12
CA2416757C (en) 2011-02-15
CY1119411T1 (el) 2018-03-07
CZ304734B6 (cs) 2014-09-10
SI2682397T1 (sl) 2017-08-31
US20050124585A1 (en) 2005-06-09
EP3235823A1 (en) 2017-10-25
NO2016006I2 (no) 2016-04-19
NO20150909L (no) 2003-03-20
EP2682397B1 (en) 2017-04-19
DK1301519T4 (da) 2021-12-20
JP2011140506A (ja) 2011-07-21
JP2004504402A (ja) 2004-02-12
NO20030270L (no) 2003-03-20
PL360490A1 (en) 2004-09-06
ES2536972T5 (es) 2022-04-06
AP2003002724A0 (en) 2003-06-30
PT2682397T (pt) 2017-05-31
AU2001282941C1 (en) 2016-12-22
NO20120466L (no) 2003-03-20
BRPI0112646B1 (pt) 2017-10-17
HK1243711A1 (en) 2018-07-20
HRP20030047A2 (en) 2007-08-31
CZ2003413A3 (cs) 2003-12-17
FR16C0013I1 (fr) 2016-05-27
US20050124584A1 (en) 2005-06-09
PL213214B1 (pl) 2013-01-31
LTPA2016009I1 (lt) 2016-04-25
NZ523438A (en) 2005-02-25
IS2985B (is) 2017-09-15
US20030219727A1 (en) 2003-11-27
CA2725819C (en) 2015-09-22
NO336718B1 (no) 2015-10-26
US20040018150A1 (en) 2004-01-29
US20080227754A1 (en) 2008-09-18
ES2627903T3 (es) 2017-08-01
OA12393A (en) 2006-04-18
LTC1301519I2 (lt) 2023-02-27
CY2016008I2 (el) 2016-12-14
US20050159392A1 (en) 2005-07-21
US20050009043A1 (en) 2005-01-13
CY2016008I1 (el) 2016-12-14
PT1301519E (pt) 2015-06-11
BR0112646A (pt) 2003-06-24
WO2002008241A3 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
BE2017C009I2 (nl)
BE2014C019I2 (nl)
BE2013C048I2 (nl)
BE2011C041I2 (nl)
JP2001255661A5 (nl)
JP2001292654A5 (nl)
CN3139997S (nl)
CN3141400S (nl)
AU2000280296A8 (nl)
AU2000278563A8 (nl)
BY5592C1 (nl)
BY7030C1 (nl)
CN3134731S (nl)
AU2000266391A8 (nl)
CN3135584S (nl)
CN3135921S (nl)
CN3136262S (nl)
CN3137238S (nl)
CN3137472S (nl)
CN3137473S (nl)
CN3139848S (nl)
CN3139849S (nl)
CN3139851S (nl)
CN3139852S (nl)
CN3135513S (nl)